Posted by Michael Wonder on 18 Feb 2026
Sandoz receives US FDA approval to expand Enzeevu (aflibercept-abzv) label for multiple retinal indications
18 February 2026 - Sandoz today announced that the US FDA has approved an expanded label for Enzeevu (aflibercept-abzv), to include multiple retinal indications.
Enzeevu was originally approved by the FDA for the treatment of neovascular (wet) age-related macular degeneration in August 2024.
Enzeevu is expected to launch in US in Q4, 2026.
